Original Research
Published on 24 Oct 2023
The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
in Hematologic Malignancies
- 5,687 views
- 10 citations